Jill P Smith

Summary

Affiliation: Pennsylvania State University
Country: USA

Publications

  1. ncbi Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression
    Gail L Matters
    Department of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA 17011, USA
    Pancreas 38:e151-61. 2009
  2. ncbi Characterization of the CCK-C (cancer) receptor in human pancreatic cancer
    Jill P Smith
    Department of Medicine, Pennsylvania State University, College of Medicine, Hershey, PA 17033, USA
    Int J Mol Med 10:689-94. 2002
  3. ncbi Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial
    Jill P Smith
    Department of Medicine, The Pennsylvania State University, College of Medicine, GI Medicine H 045, 500 University Drive, Hershey, PA 17033, USA
    Dig Dis Sci 56:2088-97. 2011
  4. ncbi The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Pancreas 29:271-7. 2004
  5. ncbi Amantadine therapy for chronic hepatitis C
    Jill P Smith
    Department of Medicine, Pennsylvania State College of Medicine, The Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    J Gen Intern Med 19:662-8. 2004
  6. ncbi Treatment of advanced pancreatic cancer with opioid growth factor: phase I
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Anticancer Drugs 15:203-9. 2004
  7. ncbi Functional significance of gastrin gene expression in human cancer cells
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, The Milton S Hershey Medical Center, Hershey, PA 17033, USA
    Regul Pept 117:167-73. 2004
  8. ncbi Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma
    Ian S Zagon
    Department of Neural and Behavioral Sciences, H109, Milton S Hershey Medical Center, The Pennsylvania State University, Hershey, 17033, USA
    Cancer Chemother Pharmacol 56:510-20. 2005
  9. ncbi Role of endogenous cholecystokinin on growth of human pancreatic cancer
    Gail L Matters
    Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Int J Oncol 38:593-601. 2011
  10. ncbi Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis
    Kristin K Fino
    Department of Medicine, College of Medicine, Pennsylvania State University, Hershey, 17033, USA
    Am J Physiol Gastrointest Liver Physiol 302:G1244-52. 2012

Collaborators

Detail Information

Publications15

  1. ncbi Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression
    Gail L Matters
    Department of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, PA 17011, USA
    Pancreas 38:e151-61. 2009
    ..This study evaluated the effects of gastrin messenger RNA (mRNA) down-regulation on growth of human pancreatic cancer...
  2. ncbi Characterization of the CCK-C (cancer) receptor in human pancreatic cancer
    Jill P Smith
    Department of Medicine, Pennsylvania State University, College of Medicine, Hershey, PA 17033, USA
    Int J Mol Med 10:689-94. 2002
    ..The term CCK-C or 'cancer' receptor has been proposed to signify the relationship of this receptor to neoplasia...
  3. ncbi Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial
    Jill P Smith
    Department of Medicine, The Pennsylvania State University, College of Medicine, GI Medicine H 045, 500 University Drive, Hershey, PA 17033, USA
    Dig Dis Sci 56:2088-97. 2011
    ..We hypothesize that the endogenous opioid system is involved in inflammatory bowel disease, and antagonism of the opioid-opioid receptor will lead to reversal of inflammation...
  4. ncbi The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Pancreas 29:271-7. 2004
    ..The aim of this study was to evaluate whether the CCK-C receptor, a splice variant of the CCK-B receptor, in human pancreatic cancer cells was associated with accelerated cancer cell growth...
  5. ncbi Amantadine therapy for chronic hepatitis C
    Jill P Smith
    Department of Medicine, Pennsylvania State College of Medicine, The Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    J Gen Intern Med 19:662-8. 2004
    ....
  6. ncbi Treatment of advanced pancreatic cancer with opioid growth factor: phase I
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Anticancer Drugs 15:203-9. 2004
    ..Further studies are needed to determine the efficacy of OGF alone or in combination with present modes of therapy for the treatment of pancreatic cancer...
  7. ncbi Functional significance of gastrin gene expression in human cancer cells
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, The Milton S Hershey Medical Center, Hershey, PA 17033, USA
    Regul Pept 117:167-73. 2004
    ..These studies demonstrate that gastrin and the CCK-C receptor form an autocrine loop in human pancreatic cancer that plays a role in regulating growth...
  8. ncbi Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma
    Ian S Zagon
    Department of Neural and Behavioral Sciences, H109, Milton S Hershey Medical Center, The Pennsylvania State University, Hershey, 17033, USA
    Cancer Chemother Pharmacol 56:510-20. 2005
    ..This preclinical evidence shows that combined chemotherapy (e.g. gemcitabine) and biotherapy (OGF) provides an enhanced therapeutic benefit for pancreatic cancer...
  9. ncbi Role of endogenous cholecystokinin on growth of human pancreatic cancer
    Gail L Matters
    Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Int J Oncol 38:593-601. 2011
    ..Pancreatic cancer cells produce CCK and gastrin; however, the autocrine production of gastrin is more important for stimulating tumor growth...
  10. ncbi Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis
    Kristin K Fino
    Department of Medicine, College of Medicine, Pennsylvania State University, Hershey, 17033, USA
    Am J Physiol Gastrointest Liver Physiol 302:G1244-52. 2012
    ..Strategies to decrease the CCK-BR expression and activity may be beneficial for the development of new methods to improve the treatment for patients with pancreatic cancer...
  11. ncbi Low-dose naltrexone therapy improves active Crohn's disease
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    Am J Gastroenterol 102:820-8. 2007
    ..In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease...
  12. ncbi Calcium phosphosilicate nanoparticles for imaging and photodynamic therapy of cancer
    Diana M Tacelosky
    Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    Discov Med 13:275-85. 2012
    ..We will also examine novel applications of CPSNPs and PDT for the treatment of leukemia to illustrate their potential utility in cancer therapeutics...
  13. ncbi Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo
    Brian M Barth
    Department of Materials Science and Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
    ACS Nano 4:1279-87. 2010
    ..These bioconjugated CPNPs have the potential to perform as a theranostic modality, simultaneously enhancing drug delivery, targeting, and imaging of breast and pancreatic cancer tumors...
  14. ncbi Amantadine therapy for chronic hepatitis C: a dose escalation study
    Jill P Smith
    Department of Medicine, Pennsylvania State University College of Medicine, The M.S. Hershey Medical Center, Hershey, Pennsylvania 17033-0850, USA
    Am J Gastroenterol 99:1099-104. 2004
    ..CONCLUSIONS: Amantadine given at a dose of 300 mg daily is safe, and significantly lowers ALT blood levels more than 200 mg daily. The enzyme response rate does not significantly improve above 300 mg, but toxicity increases...
  15. ncbi The opioid antagonist naltrexone improves murine inflammatory bowel disease
    Gail L Matters
    Departments of Biochemistry and Molecular Biology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Immunotoxicol 5:179-87. 2008
    ..The mechanism by which NTX acts to reverse colitis is related in part to the decreased expression of pro-inflammatory cytokines...

Research Grants22

  1. GASTROINTESTINAL PEPTIDES AND PANCREATIC CANCER
    Jill Smith; Fiscal Year: 2004
    ..These studies are part of the team's long-term goal to understand the mechanisms involved in the biology of human pancreatic cancer, and contribute to the treatment and early detection of this malignancy. ..
  2. Treatment of Advanced Pancreatic Cancer with Growth Fac*
    Jill Smith; Fiscal Year: 2005
    ..Abstract Not Provided ..
  3. Effects of silencing RNAs for gastrin and CCK on human pancreatic cancer
    Jill Smith; Fiscal Year: 2007
    ..These studies are the first step in bridging the results from basic science studies into the clinical realm. If shown to be effective in the animal model, we plan to proceed to treating subjects with pancreatic cancer. ..
  4. Effects of naltrexone on active Crohn's disease
    Jill Smith; Fiscal Year: 2007
    ..Durability of response will be evaluated in a 1-month follow-up. This trial is based upon novel innovative preclinical and clinical data and may lead to a larger multi-center trial in the future. ..
  5. The Cholecystokinin-C (CCK-C) Receptor for Early Detection of Pancreatic Cancer
    Jill Smith; Fiscal Year: 2007
    ..These studies are part of the applicant's long- term goals to understand the mechanisms controlling growth of pancreatic cancer and to diagnose patients in early stage of disease to improve long-term survival. ..
  6. TREATMENT OF CHRONIC HEPATITIS C WITH AMANTADINE HYDROCHLORIDE
    Jill Smith; Fiscal Year: 2002
    ..Response to therapy will be assessed by a reduction in the hepatitis C viral RNA level and hepatic alanine aminotransferase levels. ..
  7. TREATMENT OF CHRONIC HEPATITIS C WITH AMANTADINE HYDROCHLORIDE
    Jill Smith; Fiscal Year: 2000
    ..We speculate that melatonin will cause a decrease in muscle sympathetic nerve activity and a further decrease in blood pressure during simulated upright posture. ..
  8. TREATING ADVANCED PANCREATIC CANCER WITH OPIOID GROWTH FACTOR, PHASE I
    Jill Smith; Fiscal Year: 2000
    ..The purpose of this study is to determine the appropriate dose, route of administration, side effects and duration of effects after the administration of opioid growth factor. ..
  9. TREATMENT OF HEPATITIS C WITH AMANTADINE: DOSE ESCALATION STUDY
    Jill Smith; Fiscal Year: 2000
    ..The purpose of this study is to evaluate the efficacy of amantadine in hepatitis C with higher doses of the drug. ..
  10. PEPTIDES AND PANCREATIC CANCER
    Jill Smith; Fiscal Year: 2002
    ..abstract_text> ..
  11. The Cholecystokinin-C (CCK-C) Receptor for Early Detection of Pancreatic Cancer
    Jill P Smith; Fiscal Year: 2010
    ..These studies are part of the applicant's long- term goals to understand the mechanisms controlling growth of pancreatic cancer and to diagnose patients in early stage of disease to improve long-term survival. ..